Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 365

1.

c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.

Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.

Exp Mol Pathol. 1999 Jun;66(2):140-8.

PMID:
10409442
3.

HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.

Afify AM, Werness BA, Mark HF.

Exp Mol Pathol. 1999 Jun;66(2):163-9.

PMID:
10409445
4.

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.

Cancer. 2005 Oct 1;104(7):1391-7.

5.
6.

ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.

Young SR, Liu WH, Brock JA, Smith ST.

Genes Chromosomes Cancer. 1996 Jun;16(2):130-7.

PMID:
8818660
7.

Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.

Rummukainen JK, Salminen T, Lundin J, Kytölä S, Joensuu H, Isola JJ.

Mod Pathol. 2001 Oct;14(10):1030-5.

8.

Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.

Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M, Tanaka S.

Ann Thorac Cardiovasc Surg. 2001 Aug;7(4):197-203.

PMID:
11578259
9.

Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.

Ismail MF, Aly MS, Khaled HM, Mohamed HM.

Ger Med Sci. 2009 May 6;7:Doc03. doi: 10.3205/000062.

10.

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.

Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG.

Gene. 1995 Jun 14;159(1):11-8.

PMID:
7607564
11.

HER-2/neu amplification and overexpression in endometrial carcinoma.

Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH.

Int J Gynecol Pathol. 1999 Apr;18(2):138-43.

PMID:
10202671
12.

Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.

Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y.

Int J Urol. 2006 Jun;13(6):761-6.

14.

Chromosome 8 copy numbers and the c-myc gene amplification in non-small cell lung cancer. Analysis by interphase cytogenetics.

Kubokura H, Koizumi K, Yamamoto M, Tanaka S.

Nihon Ika Daigaku Zasshi. 1999 Apr;66(2):107-12.

15.

Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.

Williams JA Jr, Wang ZR, Parrish RS, Hazlett LJ, Smith ST, Young SR.

Exp Mol Pathol. 1999 Dec;67(3):135-43.

PMID:
10600396
16.

Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.

Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS.

Mod Pathol. 1997 Aug;10(8):823-31.

PMID:
9267826
17.

Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.

Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby WA, Keeney GL, Jenkins RB.

Am J Pathol. 1993 Mar;142(3):733-41.

18.

Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.

Shimada M, Imura J, Kozaki T, Fujimori T, Asakawa S, Shimizu N, Kawaguchi R.

Oncol Rep. 2005 Apr;13(4):633-41.

PMID:
15756435
19.

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.

Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.

Cancer Res. 1995 Dec 1;55(23):5693-8.

20.

Supplemental Content

Support Center